,trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['tnbc', 'breast', 'enhertu']
#enhertu is not only the most active drug in most er+ advanced breast cancers, it is also the most active in er- her2 low (ie tnbc) #asco22 #azn #dskny 
Provides consulting services to biopharmaceutical and healthcare organizations globally. Learn more at: https://t.co/TwHtYAbhWb